This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Eli Lilly and Company.
Reference
Schlueter M, et al. Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain. ClinicoEconomics and Outcomes Research : 6 Jun 2019. Available from: URL: https://doi.org/10.2147/CEOR.S201621
Rights and permissions
About this article
Cite this article
Baricitinib preferred option in moderate-to-severe RA in Spain. PharmacoEcon Outcomes News 830, 4 (2019). https://doi.org/10.1007/s40274-019-5955-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5955-x